Metformin and other biguanides in oncology: advancing the research agenda.
about
Targeting the insulin growth factor receptor 1Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and CancerMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsTargeting LKB1 in cancer - exposing and exploiting vulnerabilitiesAMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expressionMetformin in obesity, cancer and aging: addressing controversiesAlterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metforminThe maternal womb: a novel target for cancer prevention in the era of the obesity pandemic?RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.Metformin for aging and cancer prevention.Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat.Genomics: Drugs, diabetes and cancerDiabetes and pancreatic cancer.Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts.The effect of metformin on breast cancer outcomes in patients with type 2 diabetesKetones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-GenomicsGerosuppressant metformin: less is moreNew developments in urology: urology update 2014.Metformin as an energy restriction mimetic agent for breast cancer preventionMetformin inhibits melanoma development through autophagy and apoptosis mechanisms.Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancerPhenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer CellsHyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.Recent progress in targeting cancer.Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives.NCI's provocative questions on cancer: some answers to ignite discussion.Metformin: multi-faceted protection against cancer.The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerSurvival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancerMetformin use is associated with better survival of diabetic patients with pancreatic cancerDistinct perturbation of the translatome by the antidiabetic drug metforminMetformin therapy and prostate cancer risk: a meta-analysis of observational studies.Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesionsMetformin impairs the growth of liver kinase B1-intact cervical cancer cells.Role of AMPK in UVB-induced DNA damage repair and growth control.Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review
P2860
Q24633750-9C31D3FF-FBD9-4903-B6FB-01815C2F90FDQ26782065-3C14FB5C-76E2-45A8-A57A-56A29CFAF398Q26795735-454D33D7-0D15-4064-9839-B7A8362FCED0Q26801412-FEDD31DC-44AD-4558-82F6-11E6DC28E18EQ26866512-C5646531-17A3-446B-8257-3E3673EC47CBQ28478148-DDC80B35-9EAF-4E6A-B2B0-C3683075AE88Q28480735-2DD58F6F-ACFC-4C0F-97D0-33D5C8164281Q28485299-33B7333D-16B8-4FF1-BA74-E3EBCC0D3DDEQ30404178-425A1893-84BB-4086-A47E-5020EEECC3C9Q34023922-29A5780E-6999-4994-A057-AFA973AF1970Q34283475-F087C798-C445-4E5B-8D95-FC93284B750EQ34424886-97C96E3A-57AA-43E9-9A7E-7084CD0D7854Q34468454-C3F1FF57-9125-454F-88E7-F3CE05798202Q34541943-A2A08875-7B2C-4D1B-9692-38C9ECA60387Q34634263-A37D8396-B55E-4BC2-9DFB-291927204CB4Q34979869-1E7F5DFA-EA34-4CE1-A166-621DAC6DE3D5Q35000522-350A96D1-B813-4232-8573-59D5E0A7FEE6Q35051171-313D76D0-20A7-457E-98CF-C9EA980C1C38Q35052060-AE2D301D-B29B-4B54-9C65-14BC8E244A06Q35100027-CD9531DF-5A14-4204-A0AF-6E45E524B449Q35125473-B8C2CD77-1B64-441F-B7B1-8DF138A9A4FBQ35269865-691F1A95-C1D3-480C-89C4-EDEEBD5F297FQ35550181-F8C56514-60D8-4AE1-84CE-5D1FA099F86DQ35645149-2F6FFF4E-1809-4FD8-AC58-6EF1A9E16604Q35675277-E374E38E-D076-468B-BA1B-4BB9535CEFEBQ35737581-D8889570-CB04-4848-B33B-E4880AC617CBQ35740782-D6C0BA53-C416-4DBB-ABE0-94D561B30D01Q35760937-6FD065CD-CB65-434E-8D46-7F34100B9E8EQ35764308-723C29B8-10DA-4660-9D1C-33BB951CB9F1Q35764401-0ED089B5-BB0C-4584-A759-19B4ADE5A592Q35764409-B80BDE84-15AF-4E6B-8F14-87F62EF6654AQ35882782-9CD1D921-D206-4C72-8471-DDD112F083F7Q35889935-EB6BD1F2-2FCE-4B01-8391-6311185237AAQ36053323-6B27FED0-7E26-4345-8CF6-D411CCABA705Q36061621-517C7921-D78C-4489-82FA-33114F34B10EQ36182935-B0501479-9E33-4ACF-B095-65527F51572FQ36194438-8FE84A46-9EAB-4261-AFF8-6E812B25AFD3Q36205053-9377B815-9782-406D-AC79-89F6C59D7273Q36301101-36419D1B-5DB0-4534-9DE7-5D94AA962022Q36327585-F827BECF-63C8-4AB2-87F3-0EC1E2C7DA06
P2860
Metformin and other biguanides in oncology: advancing the research agenda.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Metformin and other biguanides in oncology: advancing the research agenda.
@ast
Metformin and other biguanides in oncology: advancing the research agenda.
@en
Metformin and other biguanides in oncology: advancing the research agenda.
@nl
type
label
Metformin and other biguanides in oncology: advancing the research agenda.
@ast
Metformin and other biguanides in oncology: advancing the research agenda.
@en
Metformin and other biguanides in oncology: advancing the research agenda.
@nl
prefLabel
Metformin and other biguanides in oncology: advancing the research agenda.
@ast
Metformin and other biguanides in oncology: advancing the research agenda.
@en
Metformin and other biguanides in oncology: advancing the research agenda.
@nl
P2860
P1476
Metformin and other biguanides in oncology: advancing the research agenda.
@en
P2093
Michael Pollak
P2860
P304
P356
10.1158/1940-6207.CAPR-10-0175
P577
2010-09-01T00:00:00Z